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RI present, DM absent (N = 298); and RI and DM both present (N =
216). Serum creatinine levels were measured at —18 to 24, 0, and 24, 48,
and 72 hours following contrast administration. Prophylactic hydration
was administered pre- and post-angiography. Acute nephrotoxicity (in-
crease in serum creatinine of 1 mgldl 48 to 72 hours post-contrast) was
observed in 42 (7%) patients receiving diatrizoate compared to 19 (3%)
patients receiving iohexol, P < 0.002. Differences in nephrotoxicity
between the two contrast groups were confined to patients with RI alone
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diatrizoate were 3.3 times as likely to develop acute nephrotoxicity
compared to those receiving iohexol. Clinically severe adverse renal events
were uncommon (N = 15) and did not differ in incidence between contrast
groups (iohexol N = 6; diatrizoate N = 9). In conclusion, in patients
undergoing cardiac angiography, only those with pre-existing RI alone or
combined with DM are at higher risk for acute contrast nephrotoxicity.
The incidence of acute nephrotoxicity in these high-risk patients is
significantly less with the nonionic contrast media iohexol compared to the
ionic contrast agent diatrizoate.
Intravascular iodinated contrast media administration contin-
ues to be a common cause of hospital-acquired acute renal failure
[1, 2]. Both pre-existing renal insufficiency and diabetes mellitus
have been frequently demonstrated to significantly increase the
risk of this acute event (so-called "high-risk" patients) [3, 4].
During the past decade nonionic (low-osmolality) contrast media
have become increasingly popular for radiographic procedures
requiring intravascular contrast because they are associated with a
decreased incidence of systemic and organ toxicity compared to
conventional ionic (high-osmolality) contrast media [5]. More-
over, data from animal studies have suggested that nonionic
contrast media are less nephrotoxic than ionic contrast media
[6—ill. Despite these observations, clinical experience with non-
ionic contrast media has clearly demonstrated that these newer
contrast agents are capable of causing contrast media-induced
acute renal failure in humans [12—26]. Whether nonionic contrast
media is less likely to cause acute renal failure compared to ionic
contrast media remains unclear. Several recent investigations
addressing this question have failed to demonstrate a difference in
the incidence of nephrotoxicity between nonionic and ionic con-
trast media [16, 18, 19, 22, 23, 25, 261. However, the small number
of subjects with pre-existing renal insufficiency alone or combined
with diabetes mellitus evaluated in these previous trials, limits any
conclusions regarding the relative nephrotoxicity of nonionic
contrast media in these "high-risk" patients.
The goal of our randomized prospective study was to compare
the incidence of contrast nephrotoxicity between the nonionic
contrast agent, iohexol, and the ionic contrast agent, diatrizoate,
in a large population of both "low" and "high-risk" patients
undergoing cardiac angiography.
Methods
Organization
The lohexol Cooperative Study enrolled patients from 23
participating centers across the United States. A Safety Monitor-
ing Committee independently reviewed study data periodically to
assure that neither treatment was associated with excess patient
risk. The Committee did not recommend termination of the trial
at any point. The trial was approved by the respective Institutional
Review Boards at each participating center and all patients gave
informed consent.
Patient recruitment
Study enrollment began in July 1988 and ended in March 1991.
Hemodynamically stable male and female adult patients who were
referred for non-emergent diagnostic cardiac angiography were
eligible for recruitment. Patients who had recently received
iodinated contrast media or nephrotoxic agents, had undergone
recent surgery, had acute renal failure, malignant hypertension or
a recent change in dosage of diuretics, antihypertensives or
calcium antagonists were ineligible. Women of child bearing
potential were required to have a negative pregnancy test prior to
study participation. Pregnant or lactating women were excluded
from participation as were patients who had received any inves-
tigational drug in the 30 days prior to study entry.
Patients were categorized as "Diabetic" if they required insulin
or oral hypoglycemic agents to control hyperglycemia. Patients
with diet controlled diabetes mellitus were ineligible as were those
patients who were newly found to have hyperglycemia (plasma
glucose >140 mg/dl).
Chronicity of renal insufficiency was defined by a serum creat-
mine level at the time of study entry of 1.5 mgldl, a prior history
of chronic (6 weeks) renal insufficiency, and documentation of
previously elevated serum creatinine levels.
Patients
On entry, patients were assigned to one of four stratified study
groups: Group 1 Non-diabetic, serum creatinine <1.5 mg/dl;
Group 2 Diabetic, serum creatinine <1.5 mg/dl; Group 3 Non-
diabetic, serum creatinine 1.5 mg/dl; Group 4 Diabetic, serum
creatinine  1.5 mg/dl. Within each group and at each center,
patients were randomized to receive either the nonionic contrast
agent iohexol (Omnipaque 350) or the ionic contrast agent
diatrizoate meglumine/sodium (Renografin 76). The goal of the
study was to evaluate renal function (defined below) in 320
patients in each of the four groups.
A complete medical history and physical examination was
carried out on each patient.
Clinical and laboratoiy data collection
Information regarding all concomitant medications was col-
lected at time of study entry and all medication changes during the
course of the study were recorded. Intravenous fluids (D51/2NSS
or its equivalent at a recommended rate of 100 mllhr) were
administered beginning at least four hours prior to angiography
and were continued for 24 hours post-procedure unless clinically
contraindicated. Diagnostic cardiac angiography was carried out
according to the standard procedure of each center with the
exception of "blinded" administration of contrast media. Prepro-
cedural and procedural medications were recorded, as were
details of the angiography including procedures performed, time
of first injection of contrast and total volume administered.
A venous blood specimen for the serum creatinine value which
determined the stratified group assignment at the time of study
enrollment was drawn between 18 to 24 hours prior to the
administration of contrast medium and the analysis was per-
formed in the hospital laboratory at each of the study centers. In
addition, blood specimens for serum creatinine determination
were drawn at the same time, at 0 hours (just prior to contrast
medium administration), and 24, 48 and if possible 72 hours
following contrast medium administration and were analyzed at a
central laboratory facility (SciCor, Indianapolis, IN, USA).
Statistical analysis
The primary outcome measure for this study was prospectively
defined as an increase in serum creatinine from baseline (0 hour
specimen) of 1.0 mg/dl or more within 48 to 72 hours following
contrast administration. A patient was evaluable for renal out-
come if creatinine was followed from baseline for at least 48 hours
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post-procedure without the use of any additional contrast me-
dium. A sample size of 1160 enrolled in the four groups combined
would provide 90% power at an alpha level of 0,05 to detect the
difference between overall study incidence rates of 10 and 5% for
the two contrast media. At the same time, a sample size of 290
enrolled patients in each of the four groups would provide 80%
power at an alpha level of 0.05 to detect the difference between
group incidence rates of 15% and 7.5% for the two contrast
media. The sample size was set at 320 per group to allow for the
exclusion of patients who would require further contrast medium
or imminent surgeiy within 48 hours of the study procedure. The
occurrence of an increase in serum creatinine by 0.5 mg/dl
above baseline as well as the mean peak change from baseline in
serum creatinine were specified as secondary outcome measures.
The incidence rate for each center, patient group and treatment
was calculated and analyzed with log-linear modelling (Module 4F
of BMDP) [27] for differences between treatments and for lack of
uniformity of that treatment difference across centers and across
patient groups. Means were analyzed with an analogous three way
analysis of variance model.
The main effects of other cofactors upon the primary incidence
rate were assessed with logistic regression (Proc LOGIST of SAS)
[28]. A stepwise procedure was used to select among the follow-
ing: NYHA Classification, laboratory determined renal insuffi-
ciency (baseline serum creatinine  1.5 mg/dl vs. <1.5 mgldl),
baseline serum creatinine, diabetes mellitus, congestive heart
failure, hypertension (diastolic blood pressure 90 mm Hg, <90
mm Hg) left ventricular ejection fraction (<35%, 35%), volume
of contrast (milliliters), age (years), gender, and use of aspirin,
non-aspirin nonsteroidal anti-inflammatory agents, heparin, an-
giotensin converting enzyme inhibitors, beta-blockers, calcium
antagonists, and diuretics. In the case of angiotensin converting
enzyme inhibitors, beta-blockers, calcium antagonists and diuret-
ics, patients were required to receive stable doses for at least three
days preceding study entry. Heparin use referred to intravenous
heparin other than flush solution.
A similar procedure was used to investigate interactions of the
cofactors with treatment. The only cofactor-interactions that were
considered were renal insufficiency, diabetes mellitus, the drug
classes described above, plus all other terms mentioned above that
contributed significant main effects.
All statistical tests were two-tailed; P values of 0.05 or less for
tests for hypothesis treatment effects were considered significant;
P values of 0.10 or less were considered significant for the
exploratory tests of the interactions with treatment and for all
tests (of main effects and interactions) in the cofactor analysis.
Results
Patient ently
A total of 1390 of the 1462 patients who enrolled received study
contrast media. The 72 patients who did not receive study contrast
media were equally likely to have been assigned to iohexol (N =
34) or diatrizoate (N = 38).
Of those receiving contrast, 1196 were followed for at least 48
hours post-catheterization and were considered evaluable for the
primary renal outcome analysis. The 194 patients who were not
evaluable for renal function were as likely to have received iohexol
(N = 102) as diatrizoate (N = 92). The reasons for non-
evaluability of these patients were an immediate requirement for
Table 1. Clinical characteristics and catheterization dataa
lohexol Diatrizoate
(N = 594) (N = 602)
P
Percent value
Gender 0.75
Male 70.9 71.9
Female 29.1 28.1
Mean age years 63.8 10.5 63.7 10.3 0.92
Age distribution
50 years 90.1 89.2
70 years 32.1 30.4
Cardiac status (NYHA Class) 0.73
I or II 68.9 69.9
III or IV 31.0 29.8
History of:
Renal insufficiency 44.8 46.8
Diabetes mellitus 43.1 46.5
Prior reaction to contrast media 5.5 8.7
Physical examination
Mean weight Kg 82.1 15.9 81.9 16.9 0.63
Mean height cm 170.9 9.9 171.7 10.7 0.14
Mean supine blood pressure 134/76 22/12 136/76 23/11
mm Hg
Mean standing blood pressure 131/76 22/12 133/77 23/11
mm Hg
Concomitant medications
Calcium antagonists 66.3 65.6
Diuretics 47.5 43.4
ACE inhibitors 26.1 23.6
NSAIDS 10.9 10.8
Oral hypoglycemic agents 21.7 22.8
Insulin 24.9 25.6
Catheterization Data
Selective coronary arteriography 98.8 99.7
Left ventriculography 88.4 86.4
Mean LVEF % 54.2 16.4 54.2 15.9
Mean volume of contrast ml 140.0 56.6 139.1 54.9 0.83
Mean volume of contrast /kg 1.78 0.8 1.78 0.8 0.53
body weight
Mean total volume intravenous 2393 1362 2434 1426
hydration m11'
Abbreviations are: NYHA, New York Heart Association; LVEF, Left
ventricular ejection fraction.
a Plus-minus values are means sobTotal intravenous hydration given pre, during and post-catheterization
cardiac surgery or coronary angioplasty (N = 74), missing labo-
ratory specimens (N = 61), administration of nephrotoxic drugs(N = 21), refusal to cooperate with protocol follow-up (N = 17),
and other (N = 21).
The distribution of the 1196 patients who were evaluable for
renal function by stratification groups was as follows: normal renal
function without diabetes, N = 364 (30.4%); normal renal func-
tion with diabetes, N = 318 (26.6%); renal insufficiency without
diabetes, N = 298 (24.9%); and renal insufficiency with diabetes,
N = 216 (18.1%).
Clinical characteristics and catheterization data
As presented in Table 1, clinical characteristics and catheter-
ization data of the iohexol and diatrizoate patients who were
evaluable for renal function did not disclose any significant
differences between these two treatment groups. Recruitment
(—18 to —24 hr) and baseline (0 hr) serum creatinine values are
described in Table 2. The lower mean serum creatinine values at
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Table 2. Recruitment (R) and baseline (B) serum creatinine
values (mgldl)a
lohexoib Diatrizoate"
Total
R 1.50 0.67 1.53 0.74
B 1.36 0.64 1.39 0.71
(-)RI(-)DMR 1.16 0.24 1.14 0.24
B 1.02 0.19 1.00 0.21
(—)RI(-f-)DMR 1.11 0.26 1.14 0.23
B 0.98 0.21 0.99 0.20
(+)RI(—)DM
R 1.89 0.66 1.95 0.79
B 1.75 0.60 1.78 0.72
(+)RI(+)DMR 2.13 0.83 2.20 0.90
B 2.00 0.81 2.06 0.87
Abbreviations are: RI, renal insufficiency, DM, diabetes mellitus.
a Plus-minus values are means SD.bThe total patients in each treatment and stratification group are the
same as the N values in Table 3 and Figure 1.
baseline compared to the recruitment values in each stratification
group undoubtedly reflects the parenteral hydration administered
pre-angiography.
Renal outcome data
Figure 1 shows the numt er and percent of evaluable patients
who developed nephrotoxic ty (Methods) by treatment and strat-
ification group. In the iohe Dl group, 3.2% (19 of 591) of patients
had an increase in the serum creatinine value of 1.0 mg/dl
compared to 7.1% (42 of 592) of patients in the diatrizoate group,
a difference which was highly significant (P = 0.002). Nephrotox-
icity in both treatment groups was almost exclusively limited to
patients who had renal insufficiency without or with diabetes (Fig.
1).
The renal outcome data was also analyzed using a secondary
definition of nephrotoxicity as an increase in the baseline serum
creatinine value of 0.5 mg/dl within 48 to 72 hours after contrast
administration (Table 3). As expected, application of this more
sensitive definition resulted in an increased incidence of nephro-
toxicity in all groups but this did not effect the significant differ-
ences in nephrotoxicity between iohexol and diatrizoate (P <
0.001). Similar to the primary definition of nephrotoxicity, this
analysis demonstrated that differences in nephrotoxicity between
iohexol and diatrizoate groups were most evident in patients with
either renal insufficiency alone or combined with diabetes melli-
tus.
For the entire population, the mean SE change in the serum
creatinine value from baseline was significantly less in the iohexol
compared to the diatrizoate patients at 24 hours (0.15 0.01
mgldl vs. 0.23 0.01 mg/dl, P < 0.001) and 48 hours (0.22 0.01
mgldl vs. 0.28 0.02 mgldl, P = 0.003). There were only 324
patients with evaluable data at 72 hours. An interaction of
stratification group with treatment was significant at 24 hours (P
= 0.002) and 48 hours (P = 0.003) but not at 72 hours. The
differences between iohexol and diatrizoate groups in the mean
change from baseline in the serum creatinine were most pro-
nounced in the patients who had renal insufficiency without or
with diabetes mellitus, with the largest changes demonstrated in
the latter group (Fig. 2).
The mean SD peak change in serum creatinine for patients
who received iohexol was 0.28 0.35 mg/dl compared to 0.35
0.50 mg/dl for patients who received diatrizoate. Among patients
with an increase from baseline in serum creatinine of 1.0 mg/dl,
the mean SD peak changes in serum creatinine were 1.73 0.82
mg/dl for patients who received iohexol and 1.82 0.76 mg/dl in
patients who received diatrizoate.
Cofactors associated with nephrotoxicily
The results of the logistic regression model used to analyze
cofactors which were associated with an increased risk of neph-
rotoxicity (an increase in serum creatinine 1.0 mgldl) are
described in Table 4. Only those cofactors and their interactions
which were significantly associated (P  0.10) with nephrotoxicity
are presented. The presence of renal insufficiency (baseline serum
creatinine 1.5 mg/dl), diabetes mellitus, and male gender were
each significantly associated with an increased risk of nephrotox-
icity. Patients with renal insufficiency demonstrated a 21.1 times
(CI 7.8 to 57.4) greater risk for nephrotoxicity than patients
without renal insufficiency. Although the presence of diabetes
mellitus was associated with a 3.4 times (CI 1.8 to 6.5) greater risk
for nephrotoxicity, the frequency analysis of nephrotoxicity pre-
sented in Figure 1 demonstrates that the risk among patients
without renal insufficiency was low regardless of the diabetic
status. Cofactors analyzed in a continuous manner which were
significantly associated with an increased risk of nephrotoxicity
included baseline serum creatinine value and volume of contrast
agent administered at angiography. An analysis of the interaction
between type of contrast agent and the presence of baseline renal
insufficiency demonstrated that patients with renal insufficiency
who received diatrizoate were 3.3 times (CI 1.6 to 6.6) more likely
to develop nephrotoxicity compared to similar patients who
received iohexol. There was no significant difference between type
of contrast agent in patients without renal insufficiency.
Clinical Outcome
This study was not designed to examine differences in the
clinical consequences of the various seventies of nephrotoxicity
following contrast administration. Nonetheless, 15 of 61 patients
with acute nephrotoxicity were identified by the Safety Monitoring
Committee to have developed unusually serious adverse renal
events. Criteria for inclusion in this group included either oliguria,
a requirement for acute dialysis, or an increase in the serum
creatinine of sufficient magnitude to consider dialysis. In a few
cases, limited follow-up data suggested that the nephrotoxicity
was due to factors other than contrast (such as, cholesterol
atheroemboli). An analysis of the clinical characteristics of these
15 patients revealed that 80% were male, mean age was 68.1
10.7 years, and 66.6% had a NYHA class of III or IV. All of the
patients had pre-existing renal insufficiency with a mean baseline
creatinine value of 2.7 1.2 mg/dl (range 1.5 to 5.4 mg/dl), 73%
had concomitant diabetes mellitus, and the mean volume of
contrast administered was 144 52 ml (range 62 to 240 ml). The
type of contrast agent administered was iohexol in six patients and
diatrizoate in nine patients. Eight of the patients ultimately
required acute dialysis (N 5 iohexol; N = 3 diatrizoate)
commencing 24 hours to 6 weeks after contrast administration.
258 lohexol Cooperative Study: Nephrotoxicily of contrast media
6/14
0/1880/171 1/1531/162
Fig. 1. Percent of evaluable patients who
developed nephrotoxicity for each treatment and
stratification group following cardiac angiography.
Nephrotoxicity is defined as increase in serum
creatinine of 1.0 mg/dl from baseline (0 hour)
within 48 to 72 hours after contrast
administration. Abbreviations are: RI, renal
insufficiency; DM, diabetes mellitus. Symbols
are: (Eli) iohexol; (U) meglumine/sodium
diatrizoate.
Group
lohexol Diatrizoate
n/N (%)
(—)RI(—)DM
(—)RI(+)DM
(+)RI(—)DM
(+)RI(+)DM
Totala
16/188 (8.5)
11/153 (7.2)
18/148 (12.2)
34/102 (33.3)
79/591 (13.4)
14/171 (8.2)
18/162(11.1)
40/148 (27.0)
53/111 (47.7)
125/592 (21.1)
Discussion
The introduction of nonionic (low-osmolality) contrast media in
the 1980's was accompanied by expectations of reduced nephro-
toxicity with these newer contrast agents as a result of observa-
tions in animal studies [6—11]. Although subsequent clinical
studies demonstrated a nephrotoxic potential of nonionic contrast
media [12—261, it remains unsettled if these newer contrast agents
are associated with a lower incidence of nephrotoxicity compared
to conventional ionic contrast media, especially in patients who
are at high-risk for contrast-induced renal injury.
The purpose of the present study was to compare the incidence
of nephrotoxicity following administration of the nonionic con-
trast agent iohexol and the ionic contrast agent diatrizoate in
patients undergoing elective cardiac catheterization who were
both at "low" and "high-risk" for contrast media nephrotoxicity. It
is significant that this evaluation of 1196 patients, 514 of whom
had renal insufficiency alone or combined with diabetes mellitus,
is the largest prospective randomized trial performed to date
which has compared the incidence of nephrotoxicity between
nonionic and ionic contrast media, especially in "high-risk" pa-
tients.
In addition to the large sample size, other features in the design
of our study also deserve comment. Randomization of the study
population resulted in an equal distribution between the iohexol
and diatrizoate treatment groups in those clinical characteristics
and catheterization methods which may have affected renal
outcomes (Tables 1 and 2). Of the 1,196 patients, renal function
data were obtained in 99% at 48 hours and in 27% at 72 hours
after contrast media administration, minimizing the possibility of
acute nephrotoxicity escaping detection as a result of a post-
contrast follow up period which was too brief (that is, 24 hours).
The a priori selection of an increase in the baseline serum
creatinine value of  1.0 mg/dl within 48 to 72 hours after contrast
exposure as the primary outcome measure for evidence of con-
trast media nephrotoxicity was based on our opinion that a change
of this magnitude was clinically relevant and sufficiently large to
exclude laboratory variation as causal. Finally, strict enrollment
criteria were developed to exclude patients in whom acute neph-
rotoxicity may have been caused by factors other than contrast
media administration.
The results of our study demonstrate that the nonionic contrast
agent iohexol is associated with significantly less nephrotoxicity
than the ionic contrast agent diatrizoate in "high-risk" azotemic
patients undergoing elective cardiac angiography. In addition, our
findings demonstrate that in non-azotemic patients, regardless of
the presence or absence of diabetes mellitus, there is no evidence
of reduced nephrotoxicity by the use of the nonionic agent iohexol
compared to the ionic agent diatrizoate. Although as a result of
lower than expected incidence rates of nephrotoxicity, groups 1 to
3 (Fig. 1) were under powered to definitively exclude a difference
between contrast media types, the extremely low incidence of
nephrotoxicity in groups 1 and 2 make it unlikely that any
differences between ionic and nonionic contrast media in these
two groups which might be demonstrated with larger sample sizes
would be clinically meaningful.
Our findings of a "selective" nephrotoxic benefit of the non-
ionic contrast agent iohexol conflict with previous studies which
did not demonstrate a significant difference in nephrotoxicity
between nonionic and ionic contrast media [16, 18, 19, 25,291 or
concluded that any differences which exist are of insufficient
magnitude to be clinically significant [22, 23]. In a study by Moore
et al [26], a reduced risk of nephrotoxicity was observed in patients
with pre-existing renal insufficiency with nonionic compared to
ionic contrast media (similar to our findings) although the statis-
tical significance of the interaction was marginal (P < 0.06). The
discrepancy in findings between our study and these earlier
a,
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Table 3. Frequency of nephrotoxicity: Defined as an increase in serum
creatinine 0.5 mg/dl by treatment and stratification group
Abbreviations are: RI, renal insufficiency; DM, diabetes mellitus.
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Table 4. Summary of logistic analysis: Signifleanta cofaetors
Term
Parameter
estimate
Standard
Error P value
Estimated
odds ratio
95% Confidence
interval
Gender male vs. female + 0.79 0.32 0.014 2.2 (1.2, 4.2)
Baseline serum
Creatinine mg/dl +0.83 0.18 <0.001 — —
Diabetes mellitus + 1.12 0.33 <0.001 3.4 (1.8, 6.5)
Volume of contrast ml +0.01 0.003 <0.001 — —
Renal insufficiency
baseline serum ereatinine 1.0 mgldl +3.05 0.51 <0.001 21.1 (7.8, 57.4)
Contrast:
diatrizoate versus iohexol +0.27 0.21 NS — —
Renal insufficiency - contrast interaction +0.91 0.29 0.001 — —
Within subgroups: Diatrizoate versus iohexol
Normal renal function +0.03 0.21 — 1.3 (0.9, 2.0)
Renal insufficiency + 1.18 0.36 — 3.3 (1.6, 6.6)
Outcome was  1.0 mg/dl increase in serum creatinine.
ap 0,10
investigations is most likely due to differences in sample size and
study design. The number of patients with pre-existing renal
insufficiency alone or combined with diabetes mellitus evaluated
in previous studies was considerably smaller compared to the
number of similar "high-risk" patients in this investigation. Given
the incidences of nephrotoxicity found in our study for patients
with chronic renal insufficiency alone or combined with diabetes
mellitus, it is likely that previous studies [18, 22, 23, 25, 26] had
insufficient power to avoid a Type II error in these populations of
"high-risk" patients. This opinion is supported by a recent meta-
analysis which concluded that nonionic contrast media are less
nephrotoxic than ionic contrast media in patients with pre-existing
renal insufficiency [30]. The absence of any differences in the
incidence of nephrotoxicity between diatrizoate and iohexol in our
patients with normal renal function without or with diabetes
mellitus is, however, in agreement with previous studies, which
have primarily evaluated similar "low-risk" patients [18, 19, 24, 26,
31].
Other design characteristics of earlier investigations which may
have contributed to the discrepancy in findings between these
studies and the present investigation include a failure to prospec-
tively randomize patients into nonionic and ionic contrast media
groups [16, 19, 24], the use of historic controls [16, 24], limited
post-contrast periods for evaluation of renal function [23, 26], a
disproportionate distribution of risk factors between contrast
groups [16, 25, 26], and the administration of contrast media in
settings other than cardiac catheterization [19, 22, 24—26]. In
regards to this latter point, Moore et a! [26] have demonstrated a
higher incidence of contrast media-induced nephrotoxicity in
patients undergoing cardiac catheterization compared to patients
undergoing contrast media-enhanced body computed tomogra-
phy. This difference may have been due to greater renal vasocon-
striction with intraarterial injections as well as the larger volume
of contrast media employed during cardiac catheterization [26].
Finally, we cannot exclude the possibility that differences between
our study and previous investigations may, in part, be due to
dissimilarities in the nephrotoxic potential of the specific formu-
lations of contrast media evaluated. It is reasonable to consider
that iohexol may be less nephrotoxic and/or diatrizoate (as
Renografin) more nephrotoxic than other formulations investi-
gated.
Using a logistic regression model, we found that pre-existing
renal insufficiency, diabetes mellitus, and volume of contrast agent
administered were significant independent risk factors for con-
trast media nephrotoxicity. These findings are in agreement with
previous studies which have demonstrated similar risk factors for
contrast media-induced nephrotoxicity [3, 4, 12, 16, 20, 22, 23, 25,
26, 32, 33].
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Fig. 2. Mean SE changes in serum creatinine
levels (mg/dl) from baseline (0 hour) in patients
with renal insufficiency without (A) or with (B)
diabetes mellitus for each treatment group at each
time point following cardiac angiography.
Symbols are: (El) iohexol; ()
meglumine/sodium diatrizoate.
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Since there was no apparent difference in the incidence of more
severe forms of nephrotoxicity between iohexol and diatrizoate in
our study, and only a small number of patients required acute
dialysis, similar to previous studies [3, 17, 18, 22, 23, 25, 261, the
clinical implications of the findings in this study may be ques-
tioned. In view of the low incidence of clinically-severe acute renal
failure inherent with contrast media exposure, any conclusions of
a benefit of nonionic contrast media in reducing this form of
nephrotoxicity will require the evaluation of an even greater
number of "high-risk" patients or patients with more severe
baseline azotemia. In this regard, we agree with the comments of
Schwab et al [18] that the incidence of clinically serious nephro-
toxicity in clinical practice may be greater than that demonstrated
in research studies such as ours in which patients are carefully
selected, optimally hydrated, and free of other factors which may
predispose them to contrast nephrotoxicity. The incidence of
severe forms of nephrotoxicity in this study may have also been
reduced by the relatively high percentage of patients in both
treatment groups who were on calcium antagonists which may
have exerted a prophylactic benefit [34—36]. Until additional data
are available, it remains speculative whether the differences in
nephrotoxicity demonstrated in this study would also be evident
for more severe forms of nephrotoxicity (that is, requiring acute
dialysis) if a larger number of "high-risk" patients were evaluated.
Although not part of our study, we believe that the reduction by
nonionic contrast media in milder forms of nephrotoxicity dem-
onstrated in this study will affect clinical management and be
cost-effective. In our experience, in the hospital setting an acute
elevation of the serum creatinine of 1 mgldl or more following
contrast administration commonly leads to additional laboratory
testing and postponement of further radiographic contrast expo-
sure or surgical interventions, extending the period of hospital-
ization. Since one cannot prospectively identify which patients
with contrast nephrotoxicity will progress to more clinically seri-
ous forms of acute renal failure once serum creatinine levels start
to rise, such delays are inevitable. In an analogous manner, acute
nephrotoxicity from aminoglycosides, which is also typically mild
in nature, has been shown to substantially increase the cost of
hospital care in affected individuals [37].
In conclusion, the results of this investigation demonstrate that
the nonionic contrast agent iohexol is less nephrotoxic than the
ionic contrast agent diatrizoate in patients with pre-existing renal
insufficiency alone or combined with diabetes mellitus who un-
dergo cardiac angiography. In contrast, in patients with normal
renal function, regardless of the presence or absence of diabetes
mellitus, nonionic contrast media are not less nephrotoxic com-
pared to ionic contrast agents. Additional studies in high-risk
patients will be required to determine if nonionic contrast media
are also associated with a reduced incidence of severe nephrotox-
icity (such as what would require acute dialysis) and if a reduction
by nonionic contrast media of less severe forms of nephrotoxicity
is cost-effective.
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